Spondyloarthropathies
News
Minimal disease activity criteria in PsA fall short
The minimal disease activity criteria used to identify low disease activity in psoriatic arthritis (PsA) may not be useful as a treatment target...
News
Brodalumab met primary endpoints, deaths called ‘unrelated’
The interleukin-17 inhibitor brodalumab met its co-primary endpoints in a phase III trial of patients with moderate to severe plaque psoriasis.
Conference Coverage
Expert advises how to use shingles vaccine in rheumatology patients
News
Subtle radiographic progression in axial SpA cannot be reliably distinguished from error
Key clinical point: Subtle radiographic progression in axSpA cannot be reliably distinguished from measurement error. Major finding: Using plain...
News
Subclinical inflammation predicts progression from psoriasis to PsA
People with cutaneous psoriasis who have arthralgia and signs of subclinical inflammation on MRI are at an increased risk of progressing to...
Conference Coverage
NNTs show once-unimaginable psoriasis outcomes now readily attainable
Interleukin-17 antagonists achieve PASI-90 response in a majority of psoriasis patients.
Conference Coverage
Registry shows no increased cancer risk with biologics for psoriasis
Updated results from PSOLAR registry.
News
NSAIDs effective and safe for axSpA in the short term
The findings of a recent Cochrane review back up guidelines that recommend NSAIDs as an appropriate first-line treatment for people with axial...
Conference Coverage
Consider comorbidities in psoriasis treatment for better outcomes
Emerging data increasingly link psoriasis with cardiovascular disease, diabetes, and depression, leading one expert to suggest a more integrated...
Commentary
Biosimilar program reshapes FDA’s objectivity
News
Fibromyalgia found in 20% with spondyloarthritis; could affect management decisions
Key clinical point: Coexistence of fibromyalgia in patients diagnosed with spondyloarthritis might be slightly more frequent than previously...